Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.
- Published In:
- Frontiers in pharmacology, 17, 1736380 (2026)
- Authors:
- Wali, Adil Farooq, Rangraze, Imran, Khan, Shehla, Mufti, Uwais Bashir, El-Tanani, Mohamed, Rizzo, Manfredi
- Database ID:
- RPEP-16335
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16335APA
Wali, Adil Farooq; Rangraze, Imran; Khan, Shehla; Mufti, Uwais Bashir; El-Tanani, Mohamed; Rizzo, Manfredi. (2026). Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.. Frontiers in pharmacology, 17, 1736380. https://doi.org/10.3389/fphar.2026.1736380
MLA
Wali, Adil Farooq, et al. "Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.." Frontiers in pharmacology, 2026. https://doi.org/10.3389/fphar.2026.1736380
RethinkPeptides
RethinkPeptides Research Database. "Reassessing cancer risk with GLP-1 receptor agonists: a comp..." RPEP-16335. Retrieved from https://rethinkpeptides.com/research/wali-2026-reassessing-cancer-risk-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.